1. Home
  2. HKD vs MYGN Comparison

HKD vs MYGN Comparison

Compare HKD & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HKD

AMTD Digital Inc. (every five of which represent two)

HOLD

Current Price

$1.73

Market Cap

499.7M

Sector

Finance

ML Signal

HOLD

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$5.20

Market Cap

444.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HKD
MYGN
Founded
2003
1991
Country
France
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
499.7M
444.2M
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
HKD
MYGN
Price
$1.73
$5.20
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$7.64
AVG Volume (30 Days)
198.6K
1.3M
Earning Date
02-27-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$771,400,000.00
Revenue This Year
N/A
$6.89
Revenue Next Year
N/A
$5.35
P/E Ratio
$14.10
N/A
Revenue Growth
N/A
2.33
52 Week Low
$1.26
$3.76
52 Week High
$5.47
$8.59

Technical Indicators

Market Signals
Indicator
HKD
MYGN
Relative Strength Index (RSI) 57.91 60.79
Support Level $1.58 $4.23
Resistance Level $1.88 $5.67
Average True Range (ATR) 0.09 0.28
MACD 0.01 0.07
Stochastic Oscillator 88.14 85.78

Price Performance

Historical Comparison
HKD
MYGN

About HKD AMTD Digital Inc. (every five of which represent two)

AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. Its reportable segments are digital solutions services segment; hotel operations, hospitality and VIP services segment; media and entertainment services segment; and Strategic investments. The company generates maximum revenue from Digital solutions services segment, which provides its institutional and corporate clients with exclusive, paid access to enhance their investor communication, investor relations and corporate communication to potentially maximize their valuation, as well as providing digital solution services. Geographically, the company generates revenue from China, Hong Kong, Europe, Americas and Southeast Asia.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: